Merck & Co., Inc. (NYSE:MRK) Stock Holdings Lessened by Panoramic Investment Advisors LLC

Panoramic Investment Advisors LLC reduced its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 19.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,230 shares of the company’s stock after selling 1,050 shares during the quarter. Panoramic Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $461,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of MRK. Cantor Fitzgerald Investment Advisor L.P raised its position in shares of Merck & Co., Inc. by 94.2% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 349,588 shares of the company’s stock worth $28,683,000 after buying an additional 169,536 shares in the last quarter. BCK Partners Inc. bought a new stake in shares of Merck & Co., Inc. during the 1st quarter worth about $2,423,000. NewEdge Advisors LLC raised its position in shares of Merck & Co., Inc. by 6.3% during the 1st quarter. NewEdge Advisors LLC now owns 159,225 shares of the company’s stock worth $13,064,000 after buying an additional 9,376 shares in the last quarter. First Western Trust Bank bought a new stake in shares of Merck & Co., Inc. during the 1st quarter worth about $1,078,000. Finally, Equitable Holdings Inc. grew its stake in shares of Merck & Co., Inc. by 12.9% in the 1st quarter. Equitable Holdings Inc. now owns 36,124 shares of the company’s stock worth $2,964,000 after purchasing an additional 4,131 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MRK has been the topic of several recent research reports. TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $125.00 to $135.00 in a research note on Thursday, January 4th. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a research note on Monday, March 11th. Truist Financial reaffirmed a “buy” rating and issued a $142.00 price objective (up previously from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Finally, TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $129.71.

Read Our Latest Research Report on MRK

Insider Buying and Selling

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Merck & Co., Inc. Stock Down 0.2 %

Shares of NYSE MRK traded down $0.21 during midday trading on Wednesday, reaching $130.14. The company’s stock had a trading volume of 3,605,235 shares, compared to its average volume of 8,636,100. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The stock has a market capitalization of $329.60 billion, a price-to-earnings ratio of 929.50, a PEG ratio of 0.52 and a beta of 0.38. The stock has a 50 day simple moving average of $125.45 and a 200-day simple moving average of $113.20.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. The business had revenue of $14.63 billion for the quarter, compared to the consensus estimate of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 earnings per share. Equities research analysts predict that Merck & Co., Inc. will post 8.59 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 2.37%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.